Skip to navigation Skip to content

Psoriasis (PSOR) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051130

Expand/Collapse all sectionsExpand all


PSOR restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.
\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.pngPBS PSOR restriction and item codes

Calculator

Next assessment date (NAD) calculator

Contact details

PBS Complex Drugs Programs

Forms

Severe chronic plaque psoriasis - initial authority application (PB112)

Severe chronic plaque psoriasis - continuing authority application (PB113)

Severe chronic plaque psoriasis - change, recommencement or demonstration of response authority application (PB263)

Severe chronic plaque psoriasis paediatric - ustekinumab - initial, change, recommencement or demonstration of response authority application (PB320)

Severe chronic plaque psoriasis paediatric - ustekinumab - continuing authority application (PB319)

PASI calculation forms

PASI calculation and body diagram - whole body (PB115)

PASI calculation and body diagram - face, hand and foot form (PB114)

Services Australia website

Psoriasis - severe chronic plaque psoriasis

External websites

PBS schedule for psoriasis

FAQs from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item

Description

1

Can a patient under 18 on etanercept be approved for continuing treatment?

No. A patient under 18 can be approved for initial 16 weeks of treatment and then 8 weeks of completion of course. There is no ongoing continuing treatment.